LLY

1,003.37

-0.14%↓

JNJ

245.84

-0.14%↓

ABBV

234.53

+0.82%↑

NVS

164.44

+1.42%↑

AZN

201.91

+1.41%↑

LLY

1,003.37

-0.14%↓

JNJ

245.84

-0.14%↓

ABBV

234.53

+0.82%↑

NVS

164.44

+1.42%↑

AZN

201.91

+1.41%↑

LLY

1,003.37

-0.14%↓

JNJ

245.84

-0.14%↓

ABBV

234.53

+0.82%↑

NVS

164.44

+1.42%↑

AZN

201.91

+1.41%↑

LLY

1,003.37

-0.14%↓

JNJ

245.84

-0.14%↓

ABBV

234.53

+0.82%↑

NVS

164.44

+1.42%↑

AZN

201.91

+1.41%↑

LLY

1,003.37

-0.14%↓

JNJ

245.84

-0.14%↓

ABBV

234.53

+0.82%↑

NVS

164.44

+1.42%↑

AZN

201.91

+1.41%↑

Начало・Списък с акции・Beam Therapeutics Inc

Beam Therapeutics Inc

Отворен

СекторЗдравеопазване

27.52 -0.97

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

26.58

Максимум

28.25

Ключови измерители
By Trading Economics
Приходи	357M 244M
Продажби	104M 114M
Марж на печалбата	214.091
Служители	511
EBITDA	368M 261M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+69.92% upside

Дивиденти
By Dow Jones
Следващи печалби	4.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	37M 2.9B
Предишно отваряне	28.49
Предишно затваряне	27.52

Настроения в новините

By Acuity

50%

158 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

16.225 / 20.17 Подкрепа & съпротива

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.03.2026 г., 18:43 ч. UTC

Значими събития в новините

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

3.03.2026 г., 17:33 ч. UTC

Придобивния, сливания и поглъщания

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

3.03.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

3.03.2026 г., 23:44 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

3.03.2026 г., 23:25 ч. UTC

Пазарно говорене

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

3.03.2026 г., 23:25 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

3.03.2026 г., 22:38 ч. UTC

Значими събития в новините

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

3.03.2026 г., 22:16 ч. UTC

Печалби

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

3.03.2026 г., 22:09 ч. UTC

Печалби

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

3.03.2026 г., 22:06 ч. UTC

Печалби

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

3.03.2026 г., 22:05 ч. UTC

Печалби

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

3.03.2026 г., 22:03 ч. UTC

Печалби

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

3.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Значими събития в новините

Tech, Media & Telecom Roundup: Market Talk

3.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

3.03.2026 г., 21:45 ч. UTC

Значими събития в новините

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

3.03.2026 г., 21:37 ч. UTC

Печалби

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

3.03.2026 г., 21:26 ч. UTC

Значими събития в новините

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

3.03.2026 г., 20:31 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

3.03.2026 г., 20:04 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

3.03.2026 г., 19:17 ч. UTC

Пазарно говорене

Значими събития в новините

Gold and Silver Drop as Energy Surges -- Market Talk

3.03.2026 г., 18:43 ч. UTC

Печалби

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

3.03.2026 г., 18:29 ч. UTC

Пазарно говорене

Значими събития в новините

Global Energy Roundup: Market Talk

3.03.2026 г., 18:29 ч. UTC

Пазарно говорене

Значими събития в новините

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

3.03.2026 г., 18:22 ч. UTC

Значими събития в новините

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

3.03.2026 г., 18:22 ч. UTC

Значими събития в новините

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

3.03.2026 г., 18:17 ч. UTC

Пазарно говорене

Значими събития в новините

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

3.03.2026 г., 18:14 ч. UTC

Печалби

How Long Can Anthropic Play Defense? -- WSJ

3.03.2026 г., 17:41 ч. UTC

Значими събития в новините

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

3.03.2026 г., 17:36 ч. UTC

Значими събития в новините

Iran Conflict is Starting to Boost Gasoline Prices -- Update

3.03.2026 г., 17:28 ч. UTC

Придобивния, сливания и поглъщания

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

69.92% нагоре

12-месечна прогноза

Среден 48.75 USD 69.92%

Висок 80 USD

Нисък 26 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Beam Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

16.225 / 20.17Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

158 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.